PAR4 Antibody (YA2603)
(Synonyms: PAWR; PAR4; PRKC apoptosis WT1 regulator protein; Prostate apoptosis response 4 protein; Par-4)PAR4 Antibody (YA2603) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PAR4.
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB
-
Reactivity :
Human, Mouse, Rat
-
Formulation:
Supplied in rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
WB
WB: Western Blot
|
|---|---|
| Dilution Ratio | 1:500-1:1000 |
Product Details
PAR4 Antibody (YA2603) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PAR4.
-
Host Rabbit
-
Clonality Recombinant,Monoclonal
-
Species ReactivityHuman, Mouse, Rat
-
Observed Molecular WeightObserved band size: 40 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 37 kDa
Entrez Gene: 5074 Human ; 114774 Mouse ; 64513 Rat
SwissProt: Q96IZ0 Human ; Q925B0 Mouse ; Q62627 Rat
OMIM: 601936 Human
A synthesized peptide derived from human PAR4 aa300-340.
Endogenous
Affinity Purified
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
Protease-activated receptor 4 (PAR4/F2RL3) functions as a thrombin-responsive platelet receptor that supports hemostasis and thrombosis through platelet activation[1]. Mechanistically, PAR4 signaling contributes to calcium mobilization, dense granule secretion, P-selectin expression, platelet aggregation, and platelet-leukocyte interactions[2][3]. In thrombosis models, PAR4 is required for platelet thrombus propagation but not for the initial platelet deposition after vascular injury[2]. Compared with PAR1, PAR4 requires higher thrombin concentrations for proteolysis and produces more sustained platelet activation, making PAR4 a distinct late-phase thrombin receptor[4]. This isoform distinction supports research designs that separate early PAR1-driven platelet responses from later PAR4-dependent thrombus growth[2][4]. For experimental applications, PAR4 agonist peptides and selective antagonists such as BMS-986120 enable targeted analysis of PAR4-dependent platelet activation, high-shear thrombus formation, and antithrombotic efficacy with limited bleeding signals in reported models[5][6].
-
Subcellular Localization
Cytoplasm; Nucleus
-
Expression
Tissue_specificity:Widely expressed. Elevated expression is found in a variety of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) , Alzheimer's disease, Parkinson's disease, Huntington's disease, and stroke. Downregulated expression is found in a variety of cancers.
Induction:By apoptosis -
Subunit
Homooligomer. Interacts (via the C-terminal region) with WT1 (PubMed:8943350). Interacts with THAP1 (PubMed:12717420). Interacts with AATF (PubMed:14627703). Interacts with BACE1 (PubMed:15671026).
-
SwissProt ID
-
Synonyms
PAWR; PAR4; PRKC apoptosis WT1 regulator protein; Prostate apoptosis response 4 protein; Par-4
-
Research Field
Cell Biology
Documentation
[1]. Sambrano GR, et al. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature. 2001 Sep 6;413(6851):74-8. [Content Brief]
[2]. Vandendries ER, et al. Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):288-92. [Content Brief]
[3]. Rigg RA, et al. Protease-activated receptor 4 activity promotes platelet granule release and platelet-leukocyte interactions. Platelets. 2019;30(1):126-135. [Content Brief]
[4]. Han X, et al. PAR4 (Protease-Activated Receptor 4): PARticularly Important 4 Antiplatelet Therapy. Arterioscler Thromb Vasc Biol. 2018 Feb;38(2):287-289. [Content Brief]
[5]. Wilson SJ, et al. PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation. Arterioscler Thromb Vasc Biol. 2018 Feb;38(2):448-456. [Content Brief]
[6]. Wilson SJ, et al. PAR4 (protease-activated receptor 4) antagonism with BMS-986120 inhibits human ex vivo thrombus formation. Arterioscler Thromb Vasc Biol. 2017;37(3):448-56. [Content Brief]
Powered by Bioz
